For the quarter ending 2026-03-31, QTTB had $2,454K increase in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net income (loss) | -7,609 | 57,730 | -27,909 | - |
| Non-cash revenue from settlement of customer refund liability | - | 53,737 | - | - |
| Amortization of debt discount and issuance costs | 33 | 37 | 46 | 97 |
| Amortization of premium on short-term investments | - | 0 | 0 | 0 |
| Depreciation expense | 90 | 90 | 91 | 210 |
| Stock-based compensation expense | 1,548 | 1,469 | 1,176 | 2,610 |
| Non-cashlease expense | 163 | 158 | 158 | 306 |
| Loss from equity method investment | - | 0 | 0 | - |
| Loss on impairment of equity investment | 0 | 0 | 0 | 74 |
| Change in fair value of cvr liability | 0 | 0 | 0 | 374 |
| Change in fair value of convertible notes | - | 0 | 0 | - |
| Gain on sale of asset | - | 11,737 | - | - |
| Prepaid expenses and other current assets | -302 | 245 | -1,721 | -420 |
| Other noncurrent assets | 0 | 0 | -570 | 454 |
| Accounts payable | -226 | -94 | 63 | -2,079 |
| Operating lease liability | -168 | -157 | -155 | -300 |
| Accrued expenses and other current liabilities | -476 | 306 | -511 | -3,123 |
| Net cash used in operating activities | -6,343 | -6,180 | -4,230 | -23,133 |
| Purchases of property and equipment | - | 0 | 0 | 0 |
| Proceeds from sale of asset | - | 7,000 | - | - |
| Cash acquired in connection with reverse recapitalization | - | 0 | 0 | 0 |
| Maturities of short-term investments | - | 0 | 0 | 0 |
| Payment of reverse recapitalization transaction costs | - | 0 | 0 | 0 |
| Net cash provided by investing activities | 0 | 7,000 | 0 | 0 |
| Principal payments on venture debt | -1,563 | -1,562 | -1,563 | - |
| Proceeds from exercise of common stock options | - | 0 | 0 | 0 |
| Proceeds from borrowings under loan and security agreement | - | 0 | 0 | 0 |
| Proceeds from issuance of common stock and pre-funded warrants in registered direct offering, net of issuance costs | 10,360 | 0 | 0 | 0 |
| Net cash provided by financing activities | 8,797 | -1,562 | -1,563 | 0 |
| Net increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalents | 2,454 | -742 | -5,793 | -23,133 |
| Cash, cash equivalents, restricted cash and restricted cash equivalents at beginning of period | 48,944 | 49,686 | 78,612 | - |
| Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period | 51,398 | 48,944 | 49,686 | - |
Q32 Bio Inc. (QTTB)
Q32 Bio Inc. (QTTB)